Ovarian Cancer is the most prevalent genital cancer among women [1 3]. It accounts about 17% of genital cancer in women and sixth leading cause of cancer-related deaths among women in United States. More than 19,680 ovarian cancer cases were estimated in 2024 [4-6]. The clinical outcomes for ovarian cancer patients remain poor despite sophisticated treatment strategies. This is largely due to the complexity of the disease and the aggressive nature of its progression.3 Ovarian cancer patients received more than 5 drugs as compared to young women, this ultimately results in polypharmacy [7, 8]. Use of multiple drugs during the treatment of ovarian cancer patient is crucial for preventing disease progression. Among 100 ovarian cancer patients 81% were above 45 ages. The mean age is 54.6 with a standard deviation =11.84. 63% patient with comorbidities were included. 39% patients were diagnosed at fourth stage of ovarian cancer. 100 patients received total of 124 individual drugs with a frequency (n)=1380. All patients received at least 6 drugs with standard deviation 1.9 per prescription. 78 patients received paclitaxel and carboplatin combination in their chemotherapy. The study resulted in identifying 1095 interactions out of those 350 were pDDIs. The total pDDIs in inpatients were 496 with a mean of 4.96 per patient. Ondansetron + Domperidone were most common potential pDDIs in 79 patients followed by paclitaxel + carboplatin (78). Majority of supportive drugs produce serotonin syndrome, QTc interval prolongation, CNS depression effect and interact with the pharmacokinetic effects of other drugs. Drug duplication among the same class of drugs were seen in 12 patients. The study underscores the significant risk of Drug-Drug Interactions in ovarian cancer treatment, stressing the need for vigilant monitoring. Overall, our findings emphasize the importance of tailored prescribing to enhance patient safety among ovarian cancer patients.